Bennett Weintraub

Insider Reports History

Reporting-owner location: Hopewell, NJ
Latest reporting-owner signature: /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Bennett Weintraub

Form 4 holding Director

Apimeds Pharmaceuticals US, Inc.

Security class: Stock Option (right to buy)
Shares / value: 10,000
Estimated value
Report date: 11 Nov 2025
Price
Ownership: Direct
Underlying class: Common Stock, par value $0.01 per share
Underlying amount

Insider Reports Filed by Bennett Weintraub

4 APUS

Apimeds Pharmaceuticals US, Inc.

Report period: 11 Nov 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 13 Nov 2025, 18:43
Role: Director
Next action: Open filing details

4 APUS

Apimeds Pharmaceuticals US, Inc.

Report period: 15 Oct 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 17 Oct 2025, 19:10
Role: Director
Next action: Open filing details

4 APUS

Apimeds Pharmaceuticals US, Inc.

Report period: 16 May 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 20 May 2025, 16:46
Role: Director
Next action: Open filing details

3 APUS

Apimeds Pharmaceuticals US, Inc.

Report period: 04 Mar 2025
Transactions: 0
Transaction value: $0
Accepted by SEC: 08 May 2025, 17:24
Role: Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .